The stock of Theravance Biopharma Inc (NASDAQ:TBPH) is a huge mover today! About 652,780 shares traded hands or 192.67% up from the average. Theravance Biopharma Inc (NASDAQ:TBPH) has risen 112.85% since March 9, 2016 and is uptrending. It has outperformed by 105.43% the S&P500.
The move comes after 7 months negative chart setup for the $1.53B company. It was reported on Oct, 12 by Barchart.com. We have $30.31 PT which if reached, will make NASDAQ:TBPH worth $122.40 million less.
Analysts await Theravance Biopharma Inc (NASDAQ:TBPH) to report earnings on November, 14. They expect $-0.97 EPS, up 30.71% or $0.43 from last year’s $-1.4 per share. After $-1.06 actual EPS reported by Theravance Biopharma Inc for the previous quarter, Wall Street now forecasts -8.49% EPS growth.
Theravance Biopharma Inc (NASDAQ:TBPH) Ratings Coverage
Out of 4 analysts covering Theravance Biopharma (NASDAQ:TBPH), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Theravance Biopharma has been the topic of 5 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Robert W. Baird maintained the shares of TBPH in a report on Wednesday, August 12 with “Neutral” rating. As per Wednesday, October 12, the company rating was downgraded by Robert W. Baird. Leerink Swann initiated Theravance Biopharma Inc (NASDAQ:TBPH) rating on Thursday, May 12. Leerink Swann has “Outperform” rating and $26 price target. On Monday, June 20 the stock rating was initiated by Guggenheim with “Buy”. On Monday, August 29 the stock rating was initiated by Evercore with “Buy”.
According to Zacks Investment Research, “Theravance Biopharma, Inc. is a biopharmaceutical company. It is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (CNS)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction. Theravance Biopharma, Inc. is based in George Town, Cayman Islands.”
Insitutional Activity: The institutional sentiment increased to 3.32 in Q2 2016. Its up 1.98, from 1.34 in 2016Q1. The ratio is positive, as 5 funds sold all Theravance Biopharma Inc shares owned while 14 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 48.58 million shares or 135.18% more from 20.66 million shares in 2016Q1.
Blackrock Inc last reported 3,821 shares in the company. Nationwide Fund Advsr last reported 0% of its portfolio in the stock. Next Fincl last reported 100 shares in the company. Bank & Trust Of Montreal Can has 180 shares for 0% of their US portfolio. Manufacturers Life Ins Com The has 0% invested in the company for 23,913 shares. Panagora Asset Management holds 0.02% or 212,115 shares in its portfolio. Dimensional Fund Advsr Ltd Partnership owns 43,018 shares or 0% of their US portfolio. Fred Alger Management Inc last reported 14,000 shares in the company. Moreover, Public Employees Retirement Association Of Colorado has 0% invested in Theravance Biopharma Inc (NASDAQ:TBPH) for 12,100 shares. Baupost Grp Inc Lc Ma holds 2.26% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH) for 7.35M shares. Ladenburg Thalmann Finance Incorporated has 0% invested in the company for 17 shares. California Employees Retirement Sys owns 84,900 shares or 0% of their US portfolio. Boston has 0% invested in the company for 95,579 shares. Cormorant Asset Management Limited Company last reported 1.12 million shares in the company. Northern Tru Corporation has invested 0% of its portfolio in Theravance Biopharma Inc (NASDAQ:TBPH).
Insider Transactions: Since August 18, 2016, the stock had 0 buys, and 3 selling transactions for $1.74 million net activity. Shares for $265,967 were sold by HAUMANN BRETT K. Shares for $1.35 million were sold by Shafer Bradford J.
Another recent and important Theravance Biopharma Inc (NASDAQ:TBPH) news was published by Fool.com which published an article titled: “Why Theravance Biopharma Inc. Fell 20% in September” on October 24, 2015.
TBPH Company Profile
Theravance Biopharma, Inc. (Theravance Biopharma) is a biopharmaceutical company. The Firm is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Firm operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. The Company’s commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease (COPD). The Company’s neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases, such as diabetic nephropathy. Neprilysin (NEP) is an enzyme that degrades natriuretic peptides.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.